Dry AMD Clinical Trials

Jun 07, 2024

Wet AMD, comprising around 10% of the total AMD population, is primarily the target of pharmaceutical companies, representing a market worth billions of dollars. With only two FDA-approved treatments, dry AMD presents a substantial market potential, encompassing approximately 90% of all AMD patients. Key players...

May 27, 2022

The Dry AMD market is a billion-dollar business opportunity today as around 80–90% of individuals are affected by it. As per DelveInsight analysis, there were approximately 34.9 million cases of Dry AMD in 2021. Moreover, in 10–15% of patients with Dry AMD, the deterioration is more rapid and extensive, and they su...